Artificial saliva versus pilocarpine for xerostomia

January 1999
Palliative Medicine;1999, Vol. 13 Issue 1, p81
Academic Journal
No abstract available.


Related Articles

  • The use of pilocarpine in opioid-induced xerostomia. Mercadante, S.; Calderone, L.; Villari, P.; Serretta, R.; Sapio, M.; Casuccio, A.; Fulfaro, F. // Palliative Medicine;Nov2000, Vol. 14 Issue 6, p529 

    Determines the role of pilocarpine in reducing xerostomia due to opioid used for the management of pain in patients with advanced cancer. Safety and effectiveness of using pilocarpine; Tolerance to opioid-induced xerostomia; Comparison of salivary stimulants versus saliva substitutes.

  • A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer. Davies, A.N.; Daniels, C.; Pugh, R.; Sharma, K. // Palliative Medicine;1998, Vol. 12 Issue 2, p105 

    This was a crossover study comparing a mucin-based artificial saliva (Saliva Orthana) and pilocarpine hydrochloride (Salagen) in the management of xerostomia in patients with advanced cancer. The pilocarpine was found to be more effective than the artificial saliva in terms of mean change in...

  • Systematic literature review: xerostomia in advanced cancer patients. Hanchanale, Sarika; Adkinson, Lucy; Daniel, Sunitha; Fleming, Michelle; Oxberry, Stephen // Supportive Care in Cancer;Mar2015, Vol. 23 Issue 3, p881 

    Purpose: Dry mouth (xerostomia) is one of the commonest symptoms in cancer patients and can adversely affect quality of life. The aim of this review was to determine the effectiveness of pharmacological and non-pharmacological interventions in treating xerostomia in adult advanced cancer...

  • Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD). Agha-Hosseini, F.; Mirzaii-Dizgah, I.; Ghavamzadeh, L.; Ghavamzadeh, A.; Tohidast-Acrad, Z. // Bone Marrow Transplantation;Apr2007, Vol. 39 Issue 7, p431 

    A double-blind, placebo-controlled study was conducted to evaluate the effect of orally administered pilocarpine on unstimulated whole-saliva flow and composition in 28 patients with chronic graft-versus-host disease (cGVHD). Thirteen patients were treated with pilocarpine of 20 mg/day orally...

  • Pilocarpine moistens mouths.  // Cortlandt Forum;1/25/96, Vol. 9 Issue 1, p104 

    Questions the use of oral pilocarpine in the treatment of xerostomia of Sjogren's syndrome.

  • Untitled. Clark, Anita // Journal of the American Dental Association (JADA);Sep93, Vol. 124 Issue 9, p30 

    Highlights a report in the August 5, 1993 issue of the `New England Journal of Medicine' on the effect of pilocarpine in relieving symptoms of xerostomia after irradiation therapy for head and neck cancers. Oral dryness; Comfort of the tongue and mouth; Speaking ability; Saliva production; Side...

  • Rationale for Increasing the Starting Dose of Simvastatin. Ferguson, Martin M. // Clinical Drug Investigation;2002, Vol. 22 Issue 9, p639 

    Comments on the use of pilocarpine to treat xerostomia in patients with Sjogren's syndrome. Indications of use; Causes of dissatisfaction with the use of pilocarpine.

  • Xerostomia: Etiology and Clinical Management. Stack, Kathleen M.; Papas, Athena S. // Nutrition in Clinical Care;Jan/Feb2001, Vol. 4 Issue 1, p15 

    Abstract Xerostomia, or dry mouth, is a serious oral health problem that, when left untreated, leads to deterioration and disease in the oral cavity. Patients with dry mouth include those on xerogenic medications (including many elderly patients), those undergoing chemotherapy and radiation, and...

  • Botulinum toxin B.  // Reactions Weekly;8/30/2008, Issue 1217, p9 

    The article describes the case of a 73-year-old woman who developed xerostomia after receiving botulinum toxin B injections for spastic hemiplegia. The patient was successfully treated with pilocarpine. She developed severe xerostomia which affected her quality of life. She had impaired food...

  • Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study. Nagler, R M; Nagler, A // Bone Marrow Transplantation;5/15/99, Vol. 23 Issue 10, p1007 

    Bone marrow transplantation is considered to be the treatment of choice for various hematological and solid malignancies, as well as for bone marrow failure syndromes and some genetic diseases. Unfortunately, a great number of patients who receive allogeneic BMT suffer from graft-versus-host...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics